The Business Of Biotech 101

Member Rate applies for MassBio Member Company, Other State Bioscience Association Member Company, MassCONNECT Company, or Unemployed Individual
By registering for this course, you are eligible to receive a 10% discount applied to your registration of Business of Biotech 201. Contact courses@massbioed.org to obtain the coupon code to enter when checking out.

Description
Business of Biotech 101 explores the business considerations that drive company strategies. Students will be provided with foundational information about the BioPharma industry and regulation via instruction, storytelling, and breakout group discussions. Industry ethics will be discussed, with emphasis on historical precedents. The course touches on topics such as market share, phases of development, patient population, and safety profile. A high-level overview of Research and Development, including pre-clinical through market approval will also reviewed.

Schedule
Tuesday, June 1st, 2021 12:30-3:00 PM EST
Wednesday, June 2nd, 2021 12:30-3:00 PM EST
Friday, June 4th, 2021 12:30-3:00 PM EST
Agenda
Session 1:
Origins of the Biotech Industry: a Brief History
Addressing Unmet Medical Need
Biotechnology techniques used for therapeutics development
Biotech Entrepreneurship
Business Models of the Sector and Industries within

Session 2:
Preclinical
Clinical Development
Creating Barriers to Entry: Market Exclusivity

Session 3
Patents
Early Stage Financing

Instructor
John Tagliamonte
Chief Executive Officer, Mellitus

John Tagliamonte has more than 30 years of experience in executive leadership with responsibility for business development, finance, commercial and business operations, strategic planning, finance and legal functions with established and emerging public and private life sciences companies. As the first Entrepreneur-in-Residence with MassBio, he was responsible for forward-looking program content across the organization, while helping to develop the next generation of biotech entrepreneurs. He currently serves on the business advisory boards of therapeutic startups WntRx, Fractal, MarkTx, PhagePro and Tantu. Previously he led business development at Juniper, was Chief Business Officer of Oxyrane and held various executive business leadership roles at Anchor Therapeutics, ImmunoGen and Johnson & Johnson, as well as venture investing with Safeguard. He began his career as a scientist at Dana-Farber Cancer Institute followed by global business unit management at Bio-Rad. Mr. Tagliamonte received his M.B.A. from Boston College and his B.S. in molecular biology from Tufts University.